1American Diabetes Association. Standards of Medical Care in Diabetes-2010[J].Diabetes Care, 2010,33: si l-s61.
2Cuny T, Guerci B, Cariou B. New avenues for the pharmacological management oftype 2 diabetes: an update[J]. Ann Endocrinol (Paris), 2012 Nov, 73(5): 459-468.
3Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetestreatment[J]. Pharmacol Rev, 2008,60(4): 470-512.
4Cariou B. Harnessing the incretin system beyond glucose control: potentialcardiovascular benefits of GLP-1 receptor agonists in type 2 diabetes[J].Diabetes Metab, 2012,38(4): 298-308.
5Stephens JW. The incretin system in the management of type 2 diabetesmellitus[J]. Clin Med, 2010,10(5): 491-495.
6Holst JJ. Glucagon and glucagon-like peptides 1 and 2[J]. Results Probl CellDiffe, 2010,50:121-135.
7Nauck MA, Vardarli I, Deacon CF, et al. Secretion of glucagon-like peptide-1(GLP-1) in type 2 diabetes: what is up, what is down?[J]Diabetologia, 2011,54(1): 10-18.
8Deacon CF, Ahren B. Physiology of incretins in health and disease[J]. RevDiabet Stud, 2011,8(3): 293-306.
9Mathieu C. The scientific evidence: vildagliptin and the benefits of isletenhancement[J]. Diabetes Obes Metab, 2009, ll(Suppl 2): 9-17.
10Yabe D, Seino Y. Two incretin hormones GLP-1 and GIP: comparison of theiractions in insulin secretion and (3 cell preservation [J]. Prog Biophys Mol Biol,2011,107(2):248-256.
4Vermeire E, Wens J, Van Royen P, et al. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev, 2005(2):CD003638.
5Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults[J] .JAMA,2013,310(9):948-959.
6Unger RH.Alpha-and beta-cell interrelationships in health and disease[J] .Metabolism,1974,23(6):581-593.
7Schofield CJ,Sutherland C.Disordered insulin secretion in the development of insulin resistance and Type 2 diabetes[J] .Diabt Med,2012,29(8):972-979.
8Drucker DJ.The biology of incretin hormones[J] .Cell Metab,2006,3:153-165.
